Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).
Audreylie Lemelin(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Aaron R. Hansen(Princess Margaret Cancer Centre), J. Connor Wells(Queen's University), Ravindran Kanesvaran(University of Ioannina), Ben Tran(The Royal Melbourne Hospital), Sumanta K. Pal(City of Hope), Toni K. Choueiri(Harvard University), Matthew Scott Ernst(University of Calgary), Rana R. McKay(University of California San Diego), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Ian D. Davis(Austin Health), Kosuke Takemura(Japanese Foundation For Cancer Research), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Haoran Li(University of Utah), Guillermo de Velasco(Dana-Farber Cancer Institute), Thomas Powles(National Health Service), Camillo Porta(University of Pavia)
Cited by 3
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k